cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Nurix Therapeutics Inc
1 own
3 watching
Current Price
$0
$0.66
(5.34%)
logo-nrix
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
582.75M
52-Week High
52-Week High
20.2
52-Week Low
52-Week Low
7.52
Average Volume
Average Volume
0.11M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization582.75M
icon52-Week High20.2
icon52-Week Low7.52
iconAverage Volume0.11M
iconDividend Yield--
iconP/E Ratio--
What does the Nurix Therapeutics Inc do?
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Read More
How much money does Nurix Therapeutics Inc make?
News & Events about Nurix Therapeutics Inc.
Globe Newswire
24days ago
Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurixs two first-in-class BTK degraders in 2023 Clinical data update planned for Nurixs first-in-class CBL-B ...
Globe Newswire
2 months ago
Biomarker results are a positive demonstration of target engagement for this first-in-classCBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond to levels associated with potent anti-tumor activity in disease models SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix ...
Globe Newswire
2 months ago
Presentations highlight use of Nurixs first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy in DeTIL-0255 programSAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing ...
Globe Newswire
3 months ago
Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignanciesSAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs ...
PR Newswire
3 months ago
Thinking about buying stock in Purecycle Technologies, Sellas Life Sciences, Nurix Therapeutics, Pineapple Energy, or 89bio? Thinking about buying stock in Purecycle Technologies, Sellas Life Sciences, Nurix Therapeutics, Pineapple Energy, or 89bio? PR Newswire NEW YORK, Oct. 21, 2022 NEW YORK...
Frequently Asked Questions
Frequently Asked Questions
What is Nurix Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Nurix Therapeutics Inc shares?
plus_minus_icon
How can I buy Nurix Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Nurix Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Nurix Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Nurix Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Nurix Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Nurix Therapeutics Inc?
plus_minus_icon
What percentage is Nurix Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Nurix Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.66
(5.34%)
logo-nrix
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$12.67
$0.43 (3.56 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$12.96
$0.34 (2.66 %)
Cullinan Oncology Inc
Cullinan Oncology Inc
$11.71
$0.13 (1.08 %)
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
$2.20
$-0.06 (-2.65 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$12.67
$0.43 (3.56 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$12.96
$0.34 (2.66 %)
Cullinan Oncology Inc
Cullinan Oncology Inc
$11.71
$0.13 (1.08 %)
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
$2.20
$-0.06 (-2.65 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00